341 related articles for article (PubMed ID: 19132184)
1. Prasugrel development - claims and achievements.
Serebruany V; Shalito I; Kopyleva O
Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
3. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
6. Another view on prasugrel.
Calatzis A
Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Mariani M; Mariani G; De Servi S
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Capranzano P; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
[TBL] [Abstract][Full Text] [Related]
10. Thienopyridine antiplatelet agents: focus on prasugrel.
Freeman MK
Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
[TBL] [Abstract][Full Text] [Related]
11. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Raju NC; Eikelboom JW; Hirsh J
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel: Clinical development and therapeutic application.
Guerra DR; Tcheng JE
Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
[TBL] [Abstract][Full Text] [Related]
13. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of prasugrel, a novel thienopyridine.
Angiolillo DJ; Bates ER; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S16-22. PubMed ID: 18657682
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Thomas D; Giugliano RP
Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
Koo MH; Nawarskas JJ; Frishman WH
Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel for arterial coronary thrombosis.
Serebruany V; Makarov L
Drugs Today (Barc); 2009 Feb; 45(2):83-91. PubMed ID: 19343228
[TBL] [Abstract][Full Text] [Related]
18. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
19. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
Siller-Matula J; Schrör K; Wojta J; Huber K
Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]